SCHEMBL5015240

SCHEMBL5015240

NC(=O)C1Cc2ccccc2OC1S(=O)(=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 1/20 0.42
MMP8 P22894 1/20 0.42
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
AKR1C3 P42330 1/20 0.36
NISCH Q9Y2I1 1/20 0.35
AOC2 O75106 5/20 0.35
MAOA P21397 5/20 0.35
MAOB P27338 5/20 0.35
DAO P14920 1/20 0.35
HSP90AB1 P08238 1/20 0.34
CA2 P00918 2/20 0.33
GABRA1 P14867 2/20 0.33
GABRB2 P47870 2/20 0.33
TP53 P04637 1/20 0.33
SIRT1 Q96EB6 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5023943 0.83 HPGD (0.39) HPGDTSHRNISCHAOC2MAOA
SCHEMBL31258232 0.74 HPGD (0.42) HPGDTSHRNISCHAOC2MAOA
SCHEMBL860446 0.71 HPGD (0.59) HPGDTSHRNISCHAOC2MAOA
SCHEMBL29974170 0.71 HPGD (0.59) HPGDTSHRNISCHAOC2MAOA
SCHEMBL31646098 0.70 AOC2 (0.40) HPGDTSHRNISCHAOC2MAOA
SCHEMBL30098429 0.69 AOC2 (0.39) HPGDTSHRNISCHAOC2MAOA
SCHEMBL25438707 0.69 HPGD (0.43) MMP3MMP8HPGDTSHRNISCH
Benzenesulfonamide SCHEMBL4672289 0.68 CA2 (0.47) HPGDTSHRCA2TP53SIRT1
SCHEMBL2279467 0.67 HPGD (0.44) MMP3MMP8HPGDTSHRNISCH
SCHEMBL23124236 0.66 HSP90AB1 (0.50) MMP3MMP8HPGDTSHRAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446127-B2 Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders SK HOLDINGS CO, LTD. (KR) 2008-11-04 US disclosed
US-20050107371-A1 Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders SK BIOPHARMACEUTICALS CO., LTD. (KR) 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107371-A1 Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders GPR119, CEL, ACACA MMP3 1799/4885MMP8 1949/4885HPGD 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.